CTLA4 and neoplasm: Building on the approval of combined CTLA-4 and PD-L1 inhibitors plus chemotherapy in advanced disease, ipilimumab was tested concurrently with cCRT, followed by nivolumab (NCT03663166, phase 1|2, n=19) (79), for patients with large tumor volume (median planning target volume 627.9 cc).